Previous close | 216.34 |
Open | 217.36 |
Bid | 215.41 x 100 |
Ask | 215.88 x 200 |
Day's range | 214.00 - 217.57 |
52-week range | 211.02 - 319.76 |
Volume | |
Avg. volume | 1,162,775 |
Market cap | 31.446B |
Beta (5Y monthly) | -0.02 |
PE ratio (TTM) | 27.16 |
EPS (TTM) | 7.94 |
Earnings date | 23 Apr 2024 - 29 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 304.23 |
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
Biogen Inc. (BIIB) closed the most recent trading day at $216.69, moving -0.65% from the previous trading session.